Valor20202021202220232024TTMGastos comerciales, generales y administrativos176.53 M591.17 M823.54 M466.32 M420.92 M—Investigación y desarrollo48.76 M155.04 M442.11 M344.51 M270.66 M—Beneficio operativo215.64 M17.55 B-466.07 M-603.02 M-505.54 M-4.31 MTotal de ingresos no operativos4.98 M-55.41 M757.66 M563.69 M693.81 M—Gastos por intereses, netos de intereses capitalizados1.49 M3.02 M1.26 M2.26 M——Ingresos no operativos, una vez deducidos los gastos por intereses3 M31.52 M454.64 M194.3 M166.17 M—Ingresos/gastos extraordinarios496 K-89.95 M301.75 M367.13 M527.64 M—Beneficio antes de impuestos216.62 M17.56 B25.24 M-153.03 M42.84 M17.48 BParticipación en los beneficios————-2.7 M—Impuestos31.44 M3.1 B-62.89 M105.32 M2.18 M-4.31 BParticipación minoritaria74.81 M5.99 B-25.73 M-158.44 M-50.25 M—Otros ingresos/gastos después de impuestos——————Beneficio neto antes de actividades interrumpidas110.37 M8.47 B113.87 M-99.92 M90.91 M21.79 BOperaciones suspendidas——————Beneficio neto110.37 M8.47 B113.87 M-99.92 M90.91 M21.79 BAjuste por dilución6.01 M5.98 M5.98 M5.98 M0—Dividendos de las acciones preferentes6.01 M5.98 M5.98 M5.98 M0—Beneficio neto diluido atribuible a los accionistas110.37 M8.47 B113.87 M-99.92 M90.91 M21.79 BBeneficio básico por acción1.0685.21.08-1.061.27—Beneficio por acción diluido0.9774.271-1.061.27191.05Número medio de acciones ordinarias98.9 M99.31 M99.5 M99.61 M71.86 M—Acciones diluidas113.66 M114.01 M114.17 M99.61 M71.86 M—EBITDA219.44 M17.64 B-311.22 M-460.5 M-408.33 M—EBIT215.64 M17.55 B-466.07 M-603.02 M-505.54 M—Costo de los ingresos67.18 M1.07 B684.46 M181.52 M140.69 M—Otros costes de producción5.82 M70.13 M140 M52.53 M37.11 M—Amortización y depreciación (flujo de caja)3.8 M84.63 M154.85 M142.52 M97.21 M4.31 M
Sinovac Biotech Ltd - (Antigua/Barbudo)
Sinovac Biotech Ltd. is a Chinese biopharmaceutical company based in Haidian District, Beijing that focuses on the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. The company was listed on the Nasdaq but the exchange halted Sinovac's trading in February 2019 due to a proxy fight. The company has faced bribery probes in China. Its COVID-19 vaccine was the target of a covert disinformation campaign by the US government and a promotional social media astroturfing campaign by the Chinese government.